Current Management of Onychomycosis and Dermatomycoses.

Three newer oral antifungal agents, itraconazole, terbinafine and fluconazole, have revolutionized treatment of superficial mycoses. The tissue pharmacokinetics of itraconazole and terbinafine allow much shorter courses of therapy- with higher efficacy-in the treatment of onychomycosis, compared to other oral agents. Itraconazole pulse dosing and terbinafine daily dosing have shown comparable efficacy against dermatophyte onychomycosis; similar itraconazole regimens have been effective against nondermatophyte infections. Refractory clinical patterns of nail disease appear to be more responsive to oral antifungal therapy when combined with adjunctive therapy, such as debridement. These agents are effective against cutaneous dermatophytosis, with shorter treatment regimens. Tinea versicolor may be treated with a single-dose, intermittent, or daily regimen of an oral azole agent, depending on the drug selected. These newer oral antifungal agents have been proven effective against tinea capitis; effective regimens are shorter than those for griseofulvin. The safety profile of these newer agents has been very favorable.